Actively Recruiting
Extracellular Vesicles, Insulin Action, and Exercise
Led by Rutgers, The State University of New Jersey · Updated on 2026-01-23
60
Participants Needed
3
Research Sites
215 weeks
Total Duration
On this page
Sponsors
R
Rutgers, The State University of New Jersey
Lead Sponsor
N
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Extracellular vesicles (EVs) play a role in obesity-induced insulin resistance and likely impact the development of cardiovascular disease. However, little is known on how EVs affect vascular insulin action in people. The purpose of this study is to understand how EVs play a role in type 2 diabetes related cardiovascular disease. This research will also study if exercise can change how EVs impact blood flow and metabolic health. This study will contribute to designing precision medicine to treat/prevent cardiovascular disease in type 2 diabetes.
CONDITIONS
Official Title
Extracellular Vesicles, Insulin Action, and Exercise
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 30 to 80 years
- HbA1c less than 5.7% and fasting glucose under 100 mg/dl to be considered normal glucose tolerance
- Diagnosis of type 2 diabetes or confirmed HbA1c of 6.5% or higher and fasting glucose of 126 mg/dl or higher
- Prescribed metformin, GLP-1 agonists, TZDs, DPP-IV inhibitors, Acarbose, or SGLT-2 inhibitors for at least 6 years
- Body mass index between 20 and 24.99 or between 25.0 and 45 kg/m2
- Not diagnosed with type 1 diabetes
- Not currently doing more than 150 minutes of exercise per week
You will not qualify if you...
- Morbid obesity with BMI over 45 kg/m2 or underweight with BMI less than 18 kg/m2
- Intolerance to insulin
- Diagnosis of type 1 diabetes or requiring insulin therapy
- Weight change of 2 kg or more in past 6 months
- Recent activity of 150 minutes or more of moderate/high intensity exercise in past 6 months
- Type 2 diabetes with HbA1c of 10.0% or higher
- Current smokers or quit smoking within past 2 years
- Prescribed metformin, GLP-1 agonists, TZDs, DPP-IV inhibitors, Acarbose, or SGLT-2 inhibitors within past 6 years
- High triglycerides (400 mg/dl or more) or high cholesterol (260 mg/dl or more)
- Kidney dysfunction based on specific lab values
- High blood pressure (160/100 mmHg or higher) at screening
- Abnormal liver function tests
- History of serious metabolic, cardiac, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, endocrine diseases or cancer affecting safety or study outcomes
- Pregnant or nursing women
- Contraindications to exercise training
- Known allergy to perflutren
- Anemia confirmed by hematocrit levels
- Possible infections at screening confirmed by blood counts
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Institute for Food, Nutrition, and Health
New Brunswick, New Jersey, United States, 08901
Actively Recruiting
2
Robert Wood Johnson University Hospital Clinical Research Center
New Brunswick, New Jersey, United States, 08901
Actively Recruiting
3
Rutgers University Loree Gymnasium
New Brunswick, New Jersey, United States, 08901
Actively Recruiting
Research Team
S
Steven K Malin, PhD
CONTACT
E
Emily M Heiston, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here